Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|September 15, 2022
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiencyMaud Maillard, Manon Launay, Bernard Royer, et al.
International Journal of Molecular Sciences|September 28, 2023
Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer PatientsAyman Al Saati, Pierre Vande Perre, Julien Plenecassagnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter StudySotheara Moeung, Christine Chevreau, Sophie Broutin, et al.
Therapeutic Drug Monitoring|October 10, 2018
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug MonitoringSotheara Moeung, Christine Chevreau, Vianney Poinsignon, et al.
Journal of Personalized Medicine|August 27, 2021
<i>DPYD</i> Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype ApproachPriscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso, et al.
Bulletin Du Cancer|July 1, 2014
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Fabienne Thomas, et al.
Fundamental & Clinical Pharmacology|March 31, 2015
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practiceMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, et al.
Neuro-Oncology|October 27, 2010
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsBirgit Geoerger, Darren Hargrave, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Cancers|December 9, 2020
Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue SarcomaMaud Maillard, Christine Chevreau, Félicien Le Louedec, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|September 15, 2022
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiencyMaud Maillard, Manon Launay, Bernard Royer, et al.
International Journal of Molecular Sciences|September 28, 2023
Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer PatientsAyman Al Saati, Pierre Vande Perre, Julien Plenecassagnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter StudySotheara Moeung, Christine Chevreau, Sophie Broutin, et al.
Therapeutic Drug Monitoring|October 10, 2018
Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug MonitoringSotheara Moeung, Christine Chevreau, Vianney Poinsignon, et al.
Journal of Personalized Medicine|August 27, 2021
<i>DPYD</i> Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype ApproachPriscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso, et al.
Bulletin Du Cancer|July 1, 2014
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Fabienne Thomas, et al.
Fundamental & Clinical Pharmacology|March 31, 2015
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practiceMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, et al.
Neuro-Oncology|October 27, 2010
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsBirgit Geoerger, Darren Hargrave, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Cancers|December 9, 2020
Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue SarcomaMaud Maillard, Christine Chevreau, Félicien Le Louedec, et al.
Pageof 9